Teleflex (TFX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 2.4% year-over-year to $764.4 million; adjusted EPS was $3.49, down 4.1% year-over-year but above expectations due to strong margin performance.

• Diversified portfolio and global footprint supported margin expansion and operating income growth, with Interventional and Vascular Access offsetting OEM softness.

• Integration of Palette Life Sciences AB (Barrigel) on track, with product momentum and 2024 revenue guidance raised to $73–$75 million.

• Share repurchase program authorized at $500 million, with $200 million executed via accelerated repurchase in Q3; net leverage at 1.7x.

• Significant pension settlement charge of $132.7 million recognized YTD due to U.S. defined benefit plan termination.

Financial highlights

• Q3 2024 GAAP revenue was $764.4 million, up 2.4% year-over-year; adjusted revenue up 2.2% on a constant currency basis.

• Adjusted gross margin was 60.8% (up 140 bps); GAAP gross margin was 56.3% (up 50 bps); adjusted operating margin was 27.3%.

• Cash flow from operations for the nine months was $435.6 million, up from $372.4 million in the prior year.

• Q3 2024 GAAP diluted EPS was $2.36, down from $2.90 in Q3 2023; adjusted EPS was $3.49, down 4.1% year-over-year.

• Net income for Q3 2024 was $111.0 million, down from $137.1 million in Q3 2023.

Outlook and guidance

• 2024 adjusted constant currency revenue growth guidance lowered to 3.5%–4% from 4.25%–5.25%; GAAP revenue expected to grow 2.9%–3.4%.

• Adjusted EPS guidance raised to $13.90–$14.20 for 2024; GAAP EPS guidance raised to $6.65–$6.95.

• Gross margin guidance raised to 60.5%–61%; operating margin guidance raised to 26.75%–27.0%.

• Fourth quarter revenue expected at $809–$824 million, up 4.6%–6.5% year-over-year on an adjusted basis.

• Foreign exchange expected to have a negative 0.15% impact on full-year revenue.